Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clinical Trials LymphomaIllinois

Lymphoma Clinical Trials in Illinois

Find 668 clinical trials for lymphoma near Illinois. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Illinois

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 101-120 of 668 trials

CompletedA Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma…NCT03144674·Birmingham, Alabama and 85 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedCollecting and Studying Tissue Samples From Patients With HIV-Associated MalignanciesRATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…NCT01567722·La Jolla, California and 13 others

RecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLThis is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or…NCT06500273·Gilbert, Arizona and 85 others

TerminatedRituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLThe purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used in combination with rituximab for patients with relapsing or refractory, low-grade or…NCT00077961·Colorado Springs, Colorado and 9 others

CompletedA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesThis is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of…NCT03310619·Duarte, California and 8 others

CompletedA Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaPatients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib.NCT03323151·Atlanta, Georgia and 13 others

CompletedPNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to…NCT02226965·Long Beach, California and 26 others

CompletedA Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined…NCT01059630·Mobile, Alabama and 120 others

RecruitingThe OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesThis is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a…NCT04329728·Duarte, California and 10 others

CompletedA Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.NCT02763319·Anaheim, California and 157 others

WithdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL.NCT04607772·Tucson, Arizona and 17 others

RecruitingTesting the Effect of Teclistamab on Recurrent Plasmablastic LymphomaThis phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement…NCT07332507·Duarte, California and 19 others

CompletedPeripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00004171·Chicago, Illinois

CompletedComparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00005964·Birmingham, Alabama and 46 others

RecruitingTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or…NCT04851119·Birmingham, Alabama and 20 others

CompletedCyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00002501·Chicago, Illinois and 14 others

TerminatedPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in participants with relapsed or refractory B-Cell NHL.NCT03645395·Whittier, California and 4 others

CompletedStudy of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior TherapiesThis study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior…NCT00670592·Chicago, Illinois and 27 others

Active not recruitingStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaFollicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes.NCT05409066·Tucson, Arizona and 272 others

CompletedAlisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaThis phase II trial studies how well alisertib works in treating patients with peripheral T-cell non-Hodgkin lymphoma that has come back after a period of improvement or has not…NCT01466881·Mobile, Alabama and 160 others

PreviousPage 6 of 34Next

Other Conditions in Illinois

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia